Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
Specific immunotherapies for CML patients targeting T cell antigens might eliminate residual CML cells after chemotherapy, in combination with imatinib or other tyrosine kinase inhibitors, and might enhance a specific graft versus leukemia effect after allogeneic stem cell transplantation without aggravating the graft versus host disease. For an effective specific immunotherapy in CML, the use of leukemia-associated antigens (LAAs) with an optimal expression pattern is required. In this work, we review known LAAs which are able to induce specific CD8 positive T cell responses and which are appropriate target structures for immunological targeting of CML cells. Moreover, an overview on LAA-targeted immunotherapeutic approaches for CML patients are given.
Greiner
Jochen
J
Department of Internal Medicine III, University of Ulm, Ulm, Germany. jochen.greiner@uniklinik-ulm.de
Schmitt
Michael
M
D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
D000951:Antigens, Neoplasm